Neuralstem Revenue and Competitors
Estimated Revenue & Valuation
- Neuralstem's estimated annual revenue is currently $1.7M per year.
- Neuralstem's estimated revenue per employee is $425,000
- Neuralstem's total funding is $39.9M.
Employee Data
- Neuralstem has 4 Employees.
- Neuralstem grew their employee count by -20% last year.
Neuralstem Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Neuralstem?
Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug (IND) application will be for the treatment of Ischemic Spastic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment. The Company hopes to submit its initial IND application to the FDA and begin its first human trial during calendar year 2007.
keywords:Biotechnology
$39.9M
Total Funding
4
Number of Employees
$1.7M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neuralstem News
... Globalstem , Cellular Dyna , International Stem Cell , Juventas Therapeutics , Mesoblast , Neuralstem , Neurogeneration , Ocata.
Neuralstem, STEMCELL Technologies, NeuroGeneration, NeuroNova AB, StemCells, Lonza, R&D Systems, Axol Bio, ReNeuron Limited, Thermo Fisher...
... play a critical role in the proliferation, differentiation, and migration process of neural stem/progenitor cells (NPC).
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces the closing of Tianjin Pharmaceutical Group International Holdings Co., ...
Neuralstem Inc. (AMEX:CUR) asked the Food & Drug Administration for permission to begin a clinical trial of a chronic spinal injury treatment using stem cells. The Rockville, Md.-based company’s Phase I clinical safety trial would employ its adult stem cell technology with cells derived from sp ...
Other Companies in Germantown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 4 | 0% | N/A |
#2 | $0.3M | 4 | 0% | N/A |
#3 | $0.6M | 4 | -20% | N/A |
#4 | $0.3M | 4 | -33% | N/A |
#5 | $0.3M | 4 | N/A | N/A |